BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 17, 2026
Home » Authors » Stacy Lawrence

Stacy Lawrence

Articles

ARTICLES

Cortera develops closed-loop neurostimulator to monitor brain, even as it provides stimulation

Jan. 2, 2019
By Stacy Lawrence
Cortera Neurotechnologies Inc. has developed a neurostimulation device that can simultaneously monitor and stimulate the brain, which they note as a first in the field. There are existing closed loop neurostimulators but enabling brain monitoring throughout stimulation had remained a technical hurdle.
Read More

Cambridge spinout aims to clear CSF toxins to treat neurodegenerative diseases

Dec. 31, 2018
By Stacy Lawrence
Medical device startups are becoming increasingly ambitious when it comes to treating diseases that are ill-served by drugs. The latest on this front is Enclear Therapies Inc., a Cambridge, Mass.-based company that is developing a device to clear toxic proteins from cerebrospinal fluid (CSF) to treat diseases such as amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP) and other neurological diseases.
Read More

Cambridge spinout aims to clear CFS toxins to treat neurodegenerative diseases

Dec. 28, 2018
By Stacy Lawrence

Smith & Nephew to buy Ceterix for up to $105M to advance meniscal repair

Dec. 24, 2018
By Stacy Lawrence

Diabetes, ophthalmics, diagnostics tech lead the way for med-tech stocks going into 2019

Dec. 21, 2018
By Stacy Lawrence
The med-tech industry turned in a strong stock market performance for the second year in a row in 2018. That's despite the massive retrenchment this quarter in the broader markets, which have fallen into negative territory after soaring earlier in the year. Pharma and biotech stocks also have been hit hard by drug pricing uncertainty and the downside of a long-time frothy market.
Read More

Cardiva gets PMA approval for the first electrophysiology procedure closure system

Dec. 20, 2018
By Stacy Lawrence

Tidepool nabs $6M grant from JDRF, Helmsley for closed-loop insulin app

Dec. 19, 2018
By Stacy Lawrence

J&J's Cerenovus starts clot retriever registry, gains CE mark in retrieval-resistant clots

Dec. 14, 2018
By Stacy Lawrence

Intervenn raises $9.4M to back AI, mass spec for blood-based, ovarian cancer detection

Dec. 13, 2018
By Stacy Lawrence

Steris and Mimedx plan to restructure and eliminate roughly 200 employees each

Dec. 6, 2018
By Stacy Lawrence
View All Articles by Stacy Lawrence

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 16, 2026.
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing